EUVIMEDEUVIMED entdecken
Crossref

Sodium-glucose co-transporter 2 inhibitor treatment in diabetic cats

Anna Lena Kraemer, Ian Ramsey

Companion Animal · 02.01.2025 · 30 (1) · 2-7

DOI: 10.12968/coan.2024.0039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Companion Animal, erschienen am 02.01.2025. Verfasst von Anna Lena Kraemer und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium-glucose co-transporter 2 inhibitors are oral anti-hyperglycaemic agents that represent a new treatment strategy in feline diabetes mellitus and remove the need for daily injections, dose adjustments and glucose curves. Velagliflozin (Senvelgo; Boehringer Ingelheim) is currently the only licensed sodium-glucose co-transporter 2 inhibitor for use in cats in the UK. It induces glucosuria and thereby lowers blood glucose concentrations, reverses glucotoxicity and improves clinical signs. The most common side effect is loose stools, but these are often self-limiting and short-lived. The most concerning complication of treatment is euglycaemic diabetic ketoacidosis, which is best avoided by appropriate patient selection and effective treatment monitoring.

Zitieren

APA

Kraemer, A. L., & Ramsey, I. (2025). Sodium-glucose co-transporter 2 inhibitor treatment in diabetic cats. Companion Animal, 30(1), 2-7. https://doi.org/10.12968/coan.2024.0039

Vancouver

Kraemer AL, Ramsey I. Sodium-glucose co-transporter 2 inhibitor treatment in diabetic cats. Companion Animal. 2025;30(1):2-7. doi:10.12968/coan.2024.0039

BibTeX
@article{Kraemer2025,
  author = {Kraemer, Anna Lena and Ramsey, Ian},
  title = {Sodium-glucose co-transporter 2 inhibitor treatment in diabetic cats},
  journal = {Companion Animal},
  year = {2025},
  volume = {30},
  number = {1},
  pages = {2--7},
  doi = {10.12968/coan.2024.0039}
}
Kostenlos starten →